An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease

多变量框架内的人工智能辅助筛查平台，用于阿尔茨海默病引起的轻度认知障碍的生物标志物

• 批准号: 10552520
• 负责人: Delia Cabrera DeBuc
• 金额: $ 3.32万
• 依托单位: ISCREEN 2 PREVENT LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10552520
• 关键词: Address; Alzheimer' s Disease; Alzheimer' s disease diagnostic; American; Biological Markers; Biophysics; Blood - brain barrier anatomy; Brain; Brain Neoplasms; Cardiovascular Diseases; Caring; Central Nervous System Agents; Central Nervous System Diseases; Cerebrospinal Fluid; Cholesterol; Cognitive; Communication impairment; Computer software; Computers; Consumption; Data; Dementia; Development; Devices; Diabetes Mellitus; Diagnosis; Diagnostic; Disease; Disease Management; Early Intervention; Elderly; Electrophysiology (science); Engineering; Epidemic; Evaluation; Eye; Failure; Fundus photography; Goals; Guidelines; Health; Healthcare; Hypertension; Image; Impaired cognition; Individual; Institutes; Light; Lighting; Magnetic Resonance Imaging; Measures; Methodology; Modality; Neuraxis; Neurobehavioral Manifestations; Neurologic; Neurology; Neurotransmitters; Onset of illness; Ophthalmology; Optic Nerve; Optics; Organ; Outcome; Pathologic; Patients; Penetrance; Persons; Phase; Physicians; Population; Positron-Emission Tomography; Protocols documentation; Raspberries; Research; Research Proposals; Retina; Risk; Risk Factors; Screening procedure; Source; Specificity; Stroke; Structure; Study Subject; Surrogate Markers; System; Technology; Testing; Time; Tissues; United States; United States Food and Drug Administration; Visual; base; brain abnormalities; clinical development; cost; dementia risk; design; diagnostic biomarker; diagnostic technologies; drug testing; effectiveness measure; health care settings; human subject; innovation; instrument; mild cognitive impairment; mortality; neurotechnology; neurotransmission; noninvasive diagnosis; novel; novel marker; novel therapeutics; portability; programs; protective factors; receptor; retinal imaging; retinal stimulation; routine care; screening; tool; transmission process

PROJECT SUMMARY Accumulating evidence indicates that every 65 seconds, someone develops Alzheimer's disease (AD) in the United States, and over 5.7 million Americans have the condition. Alzheimer's and other dementias will cost the nation $277 Billion by 2050. The major problem is that many people with cognitive impairment (CI) may not know they have it because dementia is underdiagnosed and underreported. There is a lack of low-cost and non- invasive screening instruments to automatically identify individuals at risk for CI with high accuracy. Therefore, considering the global and societal implications of the dementia epidemic, better strategies are needed to identify patients at risk for dementia. An eye health evaluation offers a unique perspective on the health of our eyes and our bodies. For example, visual observation of the retina as a diagnostic modality is already widely used to detect high blood pressure, diabetes, high cholesterol, and even brain tumors since a physician can see the optic nerve, which is part of the brain. Thus, an eye test may also be a potential solution to detect CI. Therefore, we aim to develop a low-cost, compact, and non-invasive neurotechnology supported by our multivariate biomarker methodology to address the pressing need for better diagnostics and surrogate markers of AD. We will further develop our novel fundus camera to develop a compact neurotechnology device that (1) enables non-invasive and portable retinal imaging with a new set of ring LED lights of specific narrow spectral bands, (2) integrates a light source for retinal stimulation and adds an optical design for recordings of the electrical activity of the retina, and (3) reduces the device cost >10 times compared to the current commercial devices based on unimodal technologies. These innovations will make our neurotechnology a rapid tool for assessing retinal function and structure easily usable by the non-expert operator, comfortable for the patient, and readily available in a wide range of healthcare settings globally. This project fills a critical technology gap in the field of AD diagnostics. While the number of screening tools using unimodal and expensive biomarkers continues to grow, these tools do not consider multivariate data generated during routine care in a collective and automated way. Thus, their diagnostic potential is limited. The development of our neurotechnology for detecting CI due to AD earlier, considering multifactorial variables and relevant biomarkers of ocular-brain abnormalities related to cognitive status, will allow earlier intervention and facilitate better management of the disease's primary cognitive symptoms.

项目摘要 积累的证据表明，每65秒，某人在 美国，超过570万美国人有这种状况。阿尔茨海默氏症和其他痴呆症将花费 到2050年，国家2770亿美元。主要问题是许多认知障碍（CI）可能不知道 他们之所以这样做，是因为痴呆症被诊断不足和报告不足。缺乏低成本和非成本 侵入性筛查工具以高精度自动识别有CI风险的人。所以， 考虑到痴呆症流行的全球和社会影响，需要更好的策略来确定 有痴呆症风险的患者。眼睛健康评估为我们的眼睛健康提供了独特的观点 我们的身体。例如，视觉观察视网膜作为诊断方式已被广泛用于检测 高血压，糖尿病，高胆固醇甚至脑肿瘤，因为医生可以看到视神经， 这是大脑的一部分。因此，眼睛测试也可能是检测CI的潜在解决方案。因此，我们的目标是 由我们的多元生物标志物支持的低成本，紧凑和非侵入性神经技术 解决迫切需求的方法，以便更好地诊断和替代AD标记。我们将进一步 开发我们的新颖的眼睛摄像头，以开发一种紧凑的神经技术设备，该设备（1）启用了无创的 和便携式视网膜成像，并带有一组新的特定狭窄光谱带的环LED灯，（2）集成 视网膜刺激的光源，并为视网膜电活动的记录添加了光学设计， （3）与基于单峰的当前商业设备相比，设备的成本> 10倍 技术。这些创新将使我们的神经技术成为评估视网膜功能和 结构很容易由非专家操作员使用，适合患者舒适，并且很宽 全球医疗环境范围。该项目填补了广告诊断领域的关键技术差距。 虽然使用单峰和昂贵的生物标志物的筛查工具数量继续增长，但这些工具 请勿以集体和自动化的方式考虑在常规护理期间生成的多元数据。因此，他们 诊断潜力有限。我们的神经技术的发展用于检测较早的AD引起的CI， 考虑多因素变量和与认知相关的眼脑异常的相关生物标志物 状态，将允许早期干预并促进更好地管理疾病的主要认知能力 症状。